DE60030889D1 - Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs - Google Patents

Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Info

Publication number
DE60030889D1
DE60030889D1 DE60030889T DE60030889T DE60030889D1 DE 60030889 D1 DE60030889 D1 DE 60030889D1 DE 60030889 T DE60030889 T DE 60030889T DE 60030889 T DE60030889 T DE 60030889T DE 60030889 D1 DE60030889 D1 DE 60030889D1
Authority
DE
Germany
Prior art keywords
breast cancer
tyrosine kinase
treatment
egfr tyrosine
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030889T
Other languages
English (en)
Other versions
DE60030889T2 (de
Inventor
Nigel James Bundred
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Application granted granted Critical
Publication of DE60030889D1 publication Critical patent/DE60030889D1/de
Publication of DE60030889T2 publication Critical patent/DE60030889T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60030889T 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs Expired - Lifetime DE60030889T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9925958 1999-11-02
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (2)

Publication Number Publication Date
DE60030889D1 true DE60030889D1 (de) 2006-11-02
DE60030889T2 DE60030889T2 (de) 2007-04-05

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030889T Expired - Lifetime DE60030889T2 (de) 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Country Status (21)

Country Link
US (1) US7553815B1 (de)
EP (1) EP1272188B1 (de)
JP (1) JP2003513035A (de)
KR (1) KR100785359B1 (de)
CN (1) CN1197577C (de)
AT (1) ATE339957T1 (de)
AU (1) AU779190B2 (de)
BR (1) BR0015194A (de)
CA (1) CA2389411C (de)
CY (1) CY1106285T1 (de)
DE (1) DE60030889T2 (de)
DK (1) DK1272188T3 (de)
ES (1) ES2275556T3 (de)
GB (1) GB9925958D0 (de)
IL (1) IL149176A0 (de)
MX (1) MXPA02004272A (de)
NO (1) NO323206B1 (de)
NZ (1) NZ518696A (de)
PT (1) PT1272188E (de)
WO (1) WO2001032155A2 (de)
ZA (1) ZA200203431B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522444A (en) 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1441736A2 (de) * 2001-10-29 2004-08-04 Novartis AG Verwendung von 7h-pyrrolo[2,3-d]pyrimidinderivaten in der behandlung solider tumore
ATE345130T1 (de) * 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO2003103676A2 (en) * 2002-06-05 2003-12-18 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
NZ545913A (en) 2003-09-19 2009-01-31 Astrazeneca Ab Quinazoline derivatives
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
EP2399605A1 (de) 2005-02-23 2011-12-28 Genentech, Inc. Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
NZ570381A (en) 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2405908B1 (de) 2009-03-11 2016-12-21 Ardea Biosciences, Inc. Pharmazeutische kombination von rdea119/bay 869766 und gemcitabin für die behandlung von spezifischen krebserkrankungen
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CN104271761B (zh) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
ES2332984T3 (es) * 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP0831829B1 (de) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
EP1080113A4 (de) * 1998-05-15 2002-04-17 Imclone Systems Inc Behandlung von humanen tumoren mit bestrahlung und inhibitoren der wachstumsfaktorrezeptor-tyrosinkinase
EP2059902B1 (de) 2006-08-28 2010-04-07 Koninklijke Philips Electronics N.V. Verfahren und vorrichtung zur bilderweiterung

Also Published As

Publication number Publication date
CN1387437A (zh) 2002-12-25
NO323206B1 (no) 2007-01-22
PT1272188E (pt) 2007-01-31
NZ518696A (en) 2004-12-24
NO20022065L (no) 2002-06-24
BR0015194A (pt) 2002-06-18
KR20020064306A (ko) 2002-08-07
IL149176A0 (en) 2002-11-10
US7553815B1 (en) 2009-06-30
WO2001032155A3 (en) 2002-05-10
ES2275556T3 (es) 2007-06-16
EP1272188A2 (de) 2003-01-08
KR100785359B1 (ko) 2007-12-18
DK1272188T3 (da) 2007-01-29
CY1106285T1 (el) 2011-10-12
GB9925958D0 (en) 1999-12-29
CN1197577C (zh) 2005-04-20
DE60030889T2 (de) 2007-04-05
MXPA02004272A (es) 2003-08-20
JP2003513035A (ja) 2003-04-08
ZA200203431B (en) 2003-02-26
AU1155901A (en) 2001-05-14
AU779190B2 (en) 2005-01-13
ATE339957T1 (de) 2006-10-15
WO2001032155A2 (en) 2001-05-10
CA2389411A1 (en) 2001-05-10
CA2389411C (en) 2009-09-01
EP1272188B1 (de) 2006-09-20
NO20022065D0 (no) 2002-04-30

Similar Documents

Publication Publication Date Title
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition